CMC002 - Establishing Regulatory Starting Materials & Understanding the ICH - James Mencel

DS InPharmatics' Senior Drug Substance Consultant, James Mencel continues his discussion on expedited drug development programs, specifically the importance of establishing regulatory starting materials. In this episode, Ed, Meranda and James discuss how the FDA and sponsors deal with the challenges of establishing starting materials, the role of the International Council for Harmonisation (ICH) and striking the balance between appropriate regulatory control and sustainable manufacturability.

Run time: 37:54mins

CMC002 - Establishing Regulatory Starting Materials & Understanding the ICH - James Mencel

Video Credit: DSI, a PLG Company

Takeaways:

00:54 – James continues his discussion of expedited drug development programs, focusing on the importance of establishing regulatory starting materials

07:34 – James provides best practices for working with clients who don’t want to approach the FDA proactively and curating fallback plans

11:45 – James speaks to strategies for establishing ideal regulatory starting materials

16:44 – James shares his thoughts on ICH Q11

20:39 – James expounds on the idea behind Quality by Design (QBD)

28:53 – James provides some final thoughts on the process of establishing regulatory starting materials

34:10 – Ed and Miranda thank James for joining the show

About CMC Live

FDA CMC regulations and guidance simplified through examination, real life experiences and risk-based advice. This podcast hopes to educate sponsors and individuals on agency related regulatory CMC matters. We will focus on the critical CMC issues and build programs that enhance drug development. CMC topics will include Regulatory Starting Materials, API and Drug Product Process, Formulation Development, Supply Chains, Analytical Controls. Advocating and interpreting CMC Strategy, directing CMC Operations and Quality Assurance oversight in conjunction with developing CMC submission content that represents the best interests of emerging biotech. NOT INTENDED TO BE PRESCRIPTIVE ADVICE BUT RATHER INTERPRETATION THAT IS RIGHT FOR YOU. Since 2007 we have provided our partners with innovative strategies and exceptional advice intended to enhance program development, product approval, and marketing presence.

Other Videos by this Supplier

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.